CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.

ABSTRACT:

Background

The CD47-signal regulatory protein alpha (SIRPα) 'don't eat me' signalling axis is perhaps the most prominent innate immune checkpoint to date. However, from initial clinical trials, it is evident that monotherapy with CD47-SIRPα blocking has a limited therapeutic effect at the maximum tolerated dose. Furthermore, treatment is associated with severe side effects, most notably anaemia, that are attributable to the ubiquitous expression of CD47. Nevertheless, promising clinical responses have been reported upon combination with the tumour-targeting antibody rituximab or azacytidine, although toxicity issues still hamper clinical application.

Main body

Here, we discuss the current state of CD47-SIRPα blocking therapy with a focus on limitations of current strategies,

SUBMITTER: Bouwstra R 

PROVIDER: S-EPMC9339239 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature